KILLER T CELL ACTIVITY IN PARANEOPLASTIC NEUROLOGIC SYNDROME

副肿瘤性神经系统疾病（PND）是一组不同的神经系统疾病， 在癌症背景下出现的神经系统疾病， 有免疫学基础。 据信，这些疾病是 当系统性肿瘤表达蛋白质时， 神经元，导致有效的抗肿瘤免疫和自身免疫神经元 退化 我们利用血清中的高滴度抗体 和CSF的PND患者的疾病分类和识别的目标 抗原 然而，降低抗体滴度的治疗方案显示， 无临床应答，抗体被动转移或诱导 动物体内的抗体应答不会再现这些病症。 我们提出 探索B和T细胞对临床疾病的贡献;在 特别是，我们怀疑并将专门寻找一个以前 未鉴定的T细胞成分与疾病有关。 在初步研究中，我们 已经能够找到一种特异性细胞毒性T细胞免疫的证据 在几个PND患者的血清和脊髓液中的反应。 我们将 试图改变自身免疫反应，以改善临床 结果，监测临床和免疫学参数。

The paraneoplastic neurologic diseases (PND's) are a diverse group of neurological disorders arising in the setting of cancer that are believed to have an immunological basis. It is believed that the disorders are triggered when systemic tumors express proteins normally made only in neurons, leading to effective anti-tumor immunity and autoimmune neuronal degeneration. We have utilized high titer antibodies present in the serum and CSF of PND patients to classify the disorders and identify the target antigens. However, treatment protocols that reduce antibody titers show no clinical response, and passive transfer of antibody or induction of antibody responses in animals do not reproduce the disorders. We propose to explore the contribution of B and T cells to the clinical disorder; in particular, we suspect and will specifically search for a previously unidentified T cell component to the disease. In preliminary studies, we have been able to find evidence for a specific cytotoxic T cell immune response in the serum and spinal fluid of several PND patients. We will attempt to modify the autoimmune response in order to improve clinical outcome, monitoring both clinical and immunological parameters.